This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Men's Health Screening By Top Prostate Surgeon

NEW YORK, Feb. 9, 2013 /PRNewswire/ -- On Saturday, February 16, 2013, top prostate cancer surgeon, Dr. David Samadi, will conduct free prostate cancer screenings at the Chian Federation, 4401 Broadway in Astoria, New York 11103. Prostate-specific antigen (PSA) blood tests and digital rectal exams (DRE) will be available at no charge from 2:30 pm to 6:30 pm. To schedule an appointment, men are asked to register at or call 718-204-2550.

(Photo: )

Dr. Samadi is a world-renowned prostate cancer expert and robotic prostate surgeon. As the Vice Chairman, Department of Urology and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center in New York, Dr. Samadi has performed more than 4,500 successful robotic laparoscopic prostate surgeries. His Samadi Modified Advanced Robotic Technique (SMART) surgery yields highly successful results in prostate cancer cure rate, as well as urinary continence and sexual potency after surgery

As a specialist in the diagnosis and treatment of urologic diseases and cancers, Dr. Samadi strongly encourages men to begin annual prostate screenings at age 50. African American men and men with a family history of prostate cancer are considered high risk for the disease and are advised to begin at age 40 or 45. The PSA is a simple blood test and the DRE is a painless physical exam of the prostate to check for irregularities.

Dr. Samadi calls the PSA test "an important first step" in diagnosing prostate cancer and other conditions such as benign prostatic hyperplasia (BPH). While the PSA test alone cannot confirm the presence of prostate cancer, an elevated PSA level indicates a potential issue. "When followed by a DRE and a prostate biopsy, as necessary, we can catch the disease very early and effectively eliminate it through surgery or other means," said Dr. Samadi. Localized prostate cancer is considered highly treatable through methods such as robotic prostatectomy surgery and radiation therapy.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 1.64%
FB $117.43 -0.96%
GOOG $692.36 -0.84%
TSLA $232.32 -3.92%
YHOO $36.01 -1.42%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs